Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2
proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of
care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or
other infections. Potential subjects hospitalized with pneumonia or other infections are to
be screened within 24 hours of diagnosis of ARDS.